Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $5.8 million.

  • Cue Biopharma's Non-Current Assets fell 2288.85% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.1 million, marking a year-over-year decrease of 1776.12%. This contributed to the annual value of $7.1 million for FY2024, which is 3000.2% down from last year.
  • Latest data reveals that Cue Biopharma reported Non-Current Assets of $5.8 million as of Q3 2025, which was down 2288.85% from $9.9 million recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Non-Current Assets peaked at $15.7 million during Q2 2022, and registered a low of $5.8 million during Q3 2025.
  • In the last 5 years, Cue Biopharma's Non-Current Assets had a median value of $10.1 million in 2023 and averaged $10.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 3396.66% in 2021, then soared by 6937.35% in 2022.
  • Quarter analysis of 5 years shows Cue Biopharma's Non-Current Assets stood at $14.9 million in 2021, then dropped by 5.6% to $14.1 million in 2022, then fell by 28.52% to $10.1 million in 2023, then plummeted by 30.0% to $7.1 million in 2024, then decreased by 17.41% to $5.8 million in 2025.
  • Its Non-Current Assets stands at $5.8 million for Q3 2025, versus $9.9 million for Q2 2025 and $6.3 million for Q1 2025.